Metabolic dysfunction–associated steatotic liver disease is associated with myocardial ischemia in patients with suspected or known coronary artery disease, especially in patients without obstructive coronary artery disease Authors: Yu Tian, Wenji Yu, Feifei Zhang, Jianfeng Wang, Xiaoliang Shao, Bao Liu, Xiaoyu Yang, Peng Wan, Yongjun Chen, Sijin Li, Yuetao Wang Published: 2026 ABSTRACT BackgroundTo investigate the relationship between metabolic dysfunction–associated steatotic liver disease (MASLD) and myocardial ischemia in patients with suspected or known coronary artery disease (CAD).MethodsThis retrospective study enrolled 281 patients with suspected or known CAD who underwent single-photon emission computed tomography myocardial perfusion imaging (SPECT-MPI) at the Third Affiliated Hospital of Soochow University from January 1, 2022, to December 31, 2023. The mean CT values of the liver and spleen, coronary artery calcification score (CACS), and epicardial fat volume (EFV) were acquired through non-enhanced computed tomography (CT). Myocardial ischemia is defined by SDS ≥ 2 detected by MPI. Obstructive CAD is defined as the degree of coronary artery lumen narrowing ≥ 50%. MASLD was defined as mean liver/spleen CT density ratio < 1 or mean liver CT density ≤ 40HU. Clinical data such as age, gender, body mass index (BMI), diabetes mellitus (DM) and hypertension were collected.ResultsOf the whole 281 patients, 140 (49.8%) had myocardial ischemia, and 107 (38.1%) had MASLD. Compared to the non-ischemic group, the myocardial ischemic group had higher EFV (137.11 cm³ versus 123.12 cm³) and BMI (25.31 kg/m² versus 24.40 kg/m²), a higher proportion of DM (32.0% versus 19.2%) and MASLD (56.4% versus 19.9%) (all P < 0.05). Multivariate regression analysis indicated that MASLD was the independent risk factor for myocardial ischemia (OR = 4.97, 95% CI: 2.68 ~ 9.24, P < 0.001). Smooth curve fitting results showed that the liver/spleen mean CT density ratio was linearly correlated with the risk of myocardial ischemia. MASLD is an independent risk factor for myocardial ischemia regardless of the presence of obstructive CAD. (obstructive CAD: OR = 5.04, 95% CI: 1.81 ~ 14.00, P = 0.002; without obstructive CAD: OR = 7.43, 95% CI: 2.69 ~ 20.52, P < 0.001). Higher OR value in patients without obstructive CAD indicates that the correlation is more significant.ConclusionMASLD is significantly associated with myocardial ischemia in suspected or known CAD patients, especially in patients without obstructive CAD, independent of traditional risk factors. Background Myocardial ischemia is a pathological condition characterized by an inadequate blood supply to the coronary arteries, resulting in an inability to meet the metabolic demands of the myocardium. This condition arises from an imbalance between myocardial oxygen supply and demand [1]. Myocardial ischemia is the main cause of death in cardiovascular diseases [2]. Large cohort studies have demonstrated that the presence of myocardial ischemia is independently associated with an increased incidence of major adverse cardiovascular events (MACE) [3], with the risk of MACE occurrence increased by 3.5 times [4]. Coronary artery disease (CAD) is the principal cause of myocardial ischemia, arising from both structural and functional alterations in the coronary circulation [5, 6]. However, increasing evidence reveals that over half of patients with myocardial ischemia do not exhibit obstructive CAD on coronary imaging [7], Data indicate that patients without obstructive CAD and myocardial ischemia have a 13% probability of experiencing MACE within two years [8]. This highlights the importance of identifying novel markers and mechanisms associated with functional ischemia beyond epicardial stenosis. Therefore, identifying prevention and treatment targets for myocardial ischemia in patients without obstructive CAD is of critical importance. Metabolic dysfunction–associated steatotic liver disease (MASLD, previously known as non-alcoholic fatty liver disease, NAFLD) [9], is a chronic liver disease with a rapidly escalating incidence globally, featuring a global prevalence of approximately 20–30%. MASLD is often regarded as the hepatic manifestation of metabolic syndrome and is an important indicator of systemic metabolic dysregulation, characterized by excessive fat accumulation in the liver in the absence of significant alcohol consumption [10]. Multiple shared pathophysiological mechanisms underlie the development of both MASLD and cardiovascular disease [11]. MASLD has been consistently associated with an elevated risk of coronary atherosclerosis, subclinical plaque formation, and overt cardiovascular events [12], and cardiovascular disease has emerged as a leading cause of mortality in MASLD patients [13, 14]. The link between MASLD and atherosclerosis has been substantiated across diverse populations and supported by meta-analyses. Recent investigations have suggested a potential association between MASLD and myocardial ischemia. For instance, reduced myocardial blood flow on CT perfusion imaging has been reported in patients with MASLD [15, 16]. However, the relationship between MASLD and functional myocardial ischemia remains poorly defined, particularly in patients without obstructive CAD. Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging (SPECT-MPI) is a highly accurate, evidence-based non-invasive imaging method for diagnosing myocardial ischemia [17]. Noncontrast cardiac computed tomography (CT), routinely used for coronary artery calcium score (CACS) and quantification of epicardial fat volume (EFV), while also enabling the noninvasive diagnosis of MASLD. This presents a unique opportunity to explore the interplay between MASLD and myocardial ischemia in a clinical setting. Consequently, this study aims to explore the relationship between MASLD and myocardial ischemia in patients with suspected or known CAD based on SPECT/CT. Furthermore, an analysis of subgroups based on coronary angiography (CAG) was conducted. Methods Study population This is a retrospective study. Patients with suspected or known CAD who underwent stress-rest myocardial perfusion imaging (MPI) at the Third Affiliated Hospital of Soochow University from January 1, 2022, to December 31, 2023, were consecutively included. All patients had CAG or coronary computed tomography angiography (CCTA) results within the past three months. “Known CAD” was defined as a prior diagnosis based on clinical history, or imaging evidence from CAG/CCTA. The exclusion criteria were as follows: (1) History of revascularization; (2) Patients with acute coronary syndrome (ACS) or prior myocardial infarction; (3) History of congenital heart disease; (4) History of cardiomyopathy; (5) Severe valvular heart disease or post-valve replacement surgery; (6) History of malignancy or history of radiotherapy/chemotherapy; (7) Long-term heavy alcohol consumption or history of excessive drinking (≥ 40 g/day for men, ≥ 20 g/day for women); (8) Patients with previous viral hepatitis, abnormal liver function, or cirrhosis; (9) Poor imaging quality. Figure 1 shows the flowchart of population selection. Traditional cardiovascular disease risk factors were collected by comprehensively querying the hospital’s medical records system, which included body mass index (BMI), hypertension, hyperlipidemia, diabetes mellitus (DM), smoking history, and clinical symptoms (such as angina, dyspnea, and atypical chest pain). Height and weight were measured to calculate BMI. According to the diagnostic criteria of the Chinese Obesity Task Force [18], BMI between 24 and 28 kg/m² was classified as overweight, and BMI ≥ 28 kg/m² was classified as obese. Abdominal obesity was assessed using waist circumference (≥ 90 cm for men, ≥ 85 cm for women) as the standard [19]. Hypertension was defined as a systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, or the use of antihypertensive medication. Hyperlipidemia was defined as a history of hyperlipidemia, total cholesterol > 5.2 mmol/L, low-density lipoprotein cholesterol > 3.36 mmol/L, or the use of lipid-lowering medications. DM was defined as random blood glucose ≥ 8.0 mmol/L or self-reported history of DM. Active smoking was defined as smoking within the past six months. Blood test indicators collected within one week of examination included fasting blood glucose (FBG), total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A1 (Apo-A1), apolipoprotein B (Apo-B), creatinine and uric acid (UA). The research protocol has been approved by the institutional review board or ethics committee, and informed consent has been obtained or waived in accordance with relevant regulations, either through written or telephone means. Fig. 1The flowchart of population selection. CAD, coronary artery disease; CAG, coronary angiography; CCTA, coronary computed tomography angiography The flowchart of population selection. CAD, coronary artery disease; CAG, coronary angiography; CCTA, coronary computed tomography angiography SPECT/CT image acquisition Before the examination, subjects were instructed to discontinue medications that affect heart rate or vasodilation such as β − blockers nitrates calcium channel blockers for 24–48 h, and to avoid caffeine-containing foods or drinks for at least 24 h. All subjects underwent a two-day gated stress (including 99% exercise stress and 1% adenosine drug stress) and rest myocardial perfusion imaging. Images were acquired using a dual-probes SPECT/CT system (T16 model, Siemens, Germany) 60 to 90 min after intravenous injection of 99mTc-MIBI (radiochemical purity > 95%, injected dose of 740–925 MBq). The specific parameters were as follows: magnification factor 1.45, matrix size 128 × 128, energy peak 140 keV, and a 20% window width. Using ECG gating technology, 8 frames were acquired for each R-R interval. The projection data were filtered using the 3D Flash iterative method (with 16 iterations and 2 subsets), resulting in the three-dimensional axial images of the left ventricle (short axis, horizontal long axis, and vertical long axis). All resting image acquisition procedures follow the recommendations of the relevant guidelines [20]. After completing the MPI acquisition, a low dose CT was performed for obtaining CACS, EFV and MASLD. The parameters were as follows: tube voltage 120 KV, tube current 100 mA, thickness 3 mm. The scanning range was from the plane below the tracheal carina to 1–2 cm below the diaphragm surface of the heart. The scan was completed with one breath-hold after inhalation, and the scanning time was 8–13 s. Data collected between 60% and 80% of the R-R interval. Imaging data processing and analysis Definition of myocardial ischemia SPECT-MPI images were reconstructed and analyzed using dedicated software, and the reconstructed stress-rest myocardial perfusion images were independently analyzed by two experienced nuclear medicine physicians. In cases of differing opinions, a third senior physician participated in the review, and a consensus diagnosis was made after discussion. Perfusion images were analyzed using a 17-segment model, dividing the 17 segments into the territories of left anterior descending coronary artery (LAD), left circumflex coronary artery (LCX) and right coronary artery (RCA). With a five-point continuous scoring system (0, normal; 1, mildly abnormal; 2, moderately abnormal; 3, severely abnormal; 4, absence of segmental uptake). The summed stress score (SSS) and summed rest score (SRS) were calculated from all abnormal segments in the stress and rest data. Summed difference score (SDS) was identified with subtracting SRS from SSS. Myocardial ischemia was defined as a reversible perfusion defect with summed difference score SDS ≥ 2 [21, 22]. Definition of MASLD In the right lobe of the liver, two regions of interest (ROIs) are selected, and one ROI is selected in the spleen at the same level. The area of the ROI is greater than 100 cubic millimeters (mm³). The mean values are then calculated to determine the liver/spleen CT density (Hounsfield Units, HU) ratio. MASLD was defined as having a mean liver/spleen CT density ratio < 1 or a mean liver CT value ≤ 40 HU as well as obesity/overweight, type 2 diabetes mellitus (T2DM) or metabolic disorders [23, 24]. The intra class correlation coefficient (ICC) was calculated using the randomized data table method for 20 study subjects, and the ICC for the mean CT density ratio of liver/spleen was 0.961 (95% CI: 0.910 ~ 0.983, P < 0.001). Coronary arteries calcium score CAC was identified as a dense area in the coronary artery surpassing the threshold of 130 HU. CACS was defined as the sum of calcification score of each coronary artery by using Agatston automatic analysis software [25]. The CACS is then categorized into two groups: no calcification (score = 0) and presence of calcification (score > 0). Calcification in the diagonal branches is included in the LAD score, while calcification in the obtuse marginal branches is included in the LCX score for calculation purposes. Epicardial fat volume On consecutive axial images, the adipose tissue area between the myocardium and the pericardium is manually delineated (with a predefined threshold of -190 to -30 HU). The ROI extends from the upper boundary at the pulmonary artery bifurcation to the lower boundary at the base of the heart. The EFV (cm³) and CT average value (HU) are calculated using semi-automatic measurement software, Syngo Volume [26]. Evaluation of obstructive CAD CCTA was performed using a Somatom Definition Flash dual-source spiral CT scanner (Siemens, Germany). CAG was conducted via radial or femoral artery puncture using the Seldinger technique and the Judkins method. The luminal diameter was independently assessed by two experienced cardiologists. In cases of disagreement, a third cardiologist was involved to reach a consensus. The primary focus was on evaluating the degree of stenosis in the left main coronary artery (LM)、LAD、LCX and RCA. Obstructive CAD was defined as ≥ 50% stenosis in at least one coronary artery, without obstructive CAD is a coronary artery stenosis of less than 50% (including 0% stenosis) [27, 28]. Statistical analysis Statistical analyses were performed using Empower Stats (www.empowerstats.com) and R software. Normally distributed continuous variables were expressed as mean ± standard deviation (\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\bar {\chi} \pm s$$\end{document}), while non-normally distributed continuous variables were expressed as median (P25, P75). The Kolmogorov-Smirnov test was used to assess the normality of each variable. Independent t-tests were used for normally distributed variables, while the Mann-Whitney U test was applied for non-normally distributed variables to analyze differences between two groups of quantitative data. Categorical variables were expressed as number (%) and analyzed using the chi-square test or Fisher’s exact test. In univariate analyses, Pearson correlation was used to evaluate the correlation between continuous variables, and Spearman correlation was used for categorical variables. Multivariate logistic regression analysis was used to evaluate the relationship between MASLD and myocardial ischemia. The confounding effects of covariates were evaluated by examining the association between MASLD and myocardial ischemia before and after adjusting for covariates. A covariate was considered a confounding factor if its inclusion in the basic model or exclusion from the full model changed the regression coefficient of MASLD by more than 10% or if the P-value of the covariate’s regression coefficient for Y was < 0.1. Additionally, any variables with a significant difference between the myocardial ischemia and non-ischemia groups (P < 0.05), as well as previously reported risk factors for myocardial ischemia, were retained as confounding factors. Variance inflation factor (VIF) was used to assess multicollinearity in the multivariate logistic regression analysis, with VIF>5 indicating the presence of collinearity. The relationship between the severity of MASLD and myocardial ischemia was further validated using generalized additive models (GAM) and smoothed curve fitting. Statistical significance was defined as a two-sided P-value < 0.05 [29]. Results Patient characteristics This study included a total of 281 patients, of whom 140 (49.8%) were myocardial ischemia, and 107 (38.1%) had MASLD. The mean age was 61.80 ± 10.06 years, with 152 males (54.1%). Baseline characteristics of all patients are shown in Table 1. Compared to the non-myocardial ischemia group, the EFV (137.11 ± 51.34 cm³ versus 123.12 ± 43.89 cm³), and BMI (25.31 ± 3.22 kg/m² versus 24.40 ± 3.00 kg/m²) were significantly higher in the myocardial ischemia group, (both P < 0.05). Additionally, the proportion of patients with DM [46 (32.0%) versus 27 (19.2%)] and MASLD [79 (56.4%) versus 28 (19.9%)] was higher (both P < 0.01). Table 1Baseline patient characteristicsDemographicsTotal (n = 281)Myocardial ischemia (n = 140)Non-ischemia (n = 141)P ValueAge, years61.80 ± 10.0661.11 ± 10.6862.49 ± 9.390.250Male, n (%)152 (54.1)81 (57.9)71 (50.4)0.207BMI, kg/m²24.84 ± 3.1325.31 ± 3.2224.40 ± 3.000.015*Abdominal obesity, n (%)187 (66.6)96 (68.6)91 (64.5)0.474Symptom, n (%)256 (91.1)124 (88.6)132 (95.0)0.052Current smoking, n (%)92 (32.7)57 (40.7)35 (24.8)0.009*Hypertension, n (%)193 (68.7)101 (72.1)92 (65.3)0.213Hyperlipidemias, n (%)122 (43.4)59 (42.1)63 (44.7)0.668DM, n (%)73 (26.0)46 (32.0)27 (19.2)0.009*MASLD, n (%)107 (38.1)79 (56.4)28 (19.9)< 0.001*Liver CT density, HU52.9 (47,59)50.0 (45.7, 58.0)56.0 (51.0, 60.0)< 0.001*Liver/spleen CT density1.10 ± 0.241.03 ± 0.221.17 ± 0.24< 0.001*EFV, cm3130.14 ± 48.20137.11 ± 51.34123.12 ± 43.890.017*CACS, n (%)0.1670130 (46.3)59 (42.1)71 (50.4)>0151 (53.7)81 (57.9)70 (49.7)Obstructive CAD, n (%)0.062No126 (44.8)55 (39.3)71 (50.4)Yes155 (55.2)85 (60.7)70 (49.7)FBG, mmol/L6.29 (4.97, 6.68)5.62 (4.94, 6.94)5.62 (5.00, 6.41)0.132TC, mmol/L4.05 (3.14, 4.73)3.96 (3.19,4.89)3.84 (3.11, 4.55)0.284TG, mmol/L1.84 (1.09, 2.04)1.46 (1.12, 2.14)1.47 (1.06, 1.96)0.356LDL-C, mmol/L2.28 ± 0.862.32 ± 0.842.21 ± 0.890.279HDL-C, mmol/L1.15 ± 0.301.15 ± 0.321.16 ± 0.270.466Creatinine, µmol/L69.00 ± 18.1568.28 ± 20.7969.22 ± 16.020.447UA, µmol/L336.59 ± 86.04337.87 ± 89.43333.70 ± 85.750.661Statin, n (%)233 (82.9)121 (86.4)112 (79.4)0.119Biguanides, n (%)25 (8.9)14 (10.0)11 (7.8)0.517Trimetazidine, n (%)62 (22.1)108 (77.1)111 (78.2)0.749Symptoms include angina, dyspnea, atypical chest pain, and dyspnea with angina or atypical chest pain. BMI, body mass, index; DM, diabetes mellitus; CACS, coronary artery calcification score; MASLD, Metabolic dysfunction–associated steatotic liver disease; EFV, epicardial fat volume; FBG, fasting blood glucose; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high‐density lipoprotein cholesterol; UA, uric acid. *P<0.05 Table 1Baseline patient characteristicsDemographicsTotal (n = 281)Myocardial ischemia (n = 140)Non-ischemia (n = 141)P ValueAge, years61.80 ± 10.0661.11 ± 10.6862.49 ± 9.390.250Male, n (%)152 (54.1)81 (57.9)71 (50.4)0.207BMI, kg/m²24.84 ± 3.1325.31 ± 3.2224.40 ± 3.000.015*Abdominal obesity, n (%)187 (66.6)96 (68.6)91 (64.5)0.474Symptom, n (%)256 (91.1)124 (88.6)132 (95.0)0.052Current smoking, n (%)92 (32.7)57 (40.7)35 (24.8)0.009*Hypertension, n (%)193 (68.7)101 (72.1)92 (65.3)0.213Hyperlipidemias, n (%)122 (43.4)59 (42.1)63 (44.7)0.668DM, n (%)73 (26.0)46 (32.0)27 (19.2)0.009*MASLD, n (%)107 (38.1)79 (56.4)28 (19.9)< 0.001*Liver CT density, HU52.9 (47,59)50.0 (45.7, 58.0)56.0 (51.0, 60.0)< 0.001*Liver/spleen CT density1.10 ± 0.241.03 ± 0.221.17 ± 0.24< 0.001*EFV, cm3130.14 ± 48.20137.11 ± 51.34123.12 ± 43.890.017*CACS, n (%)0.1670130 (46.3)59 (42.1)71 (50.4)>0151 (53.7)81 (57.9)70 (49.7)Obstructive CAD, n (%)0.062No126 (44.8)55 (39.3)71 (50.4)Yes155 (55.2)85 (60.7)70 (49.7)FBG, mmol/L6.29 (4.97, 6.68)5.62 (4.94, 6.94)5.62 (5.00, 6.41)0.132TC, mmol/L4.05 (3.14, 4.73)3.96 (3.19,4.89)3.84 (3.11, 4.55)0.284TG, mmol/L1.84 (1.09, 2.04)1.46 (1.12, 2.14)1.47 (1.06, 1.96)0.356LDL-C, mmol/L2.28 ± 0.862.32 ± 0.842.21 ± 0.890.279HDL-C, mmol/L1.15 ± 0.301.15 ± 0.321.16 ± 0.270.466Creatinine, µmol/L69.00 ± 18.1568.28 ± 20.7969.22 ± 16.020.447UA, µmol/L336.59 ± 86.04337.87 ± 89.43333.70 ± 85.750.661Statin, n (%)233 (82.9)121 (86.4)112 (79.4)0.119Biguanides, n (%)25 (8.9)14 (10.0)11 (7.8)0.517Trimetazidine, n (%)62 (22.1)108 (77.1)111 (78.2)0.749Symptoms include angina, dyspnea, atypical chest pain, and dyspnea with angina or atypical chest pain. BMI, body mass, index; DM, diabetes mellitus; CACS, coronary artery calcification score; MASLD, Metabolic dysfunction–associated steatotic liver disease; EFV, epicardial fat volume; FBG, fasting blood glucose; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high‐density lipoprotein cholesterol; UA, uric acid. *P<0.05 Baseline patient characteristics Symptoms include angina, dyspnea, atypical chest pain, and dyspnea with angina or atypical chest pain. BMI, body mass, index; DM, diabetes mellitus; CACS, coronary artery calcification score; MASLD, Metabolic dysfunction–associated steatotic liver disease; EFV, epicardial fat volume; FBG, fasting blood glucose; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high‐density lipoprotein cholesterol; UA, uric acid. *P<0.05 Compared with non-MASLD group, MASLD had higher BMI (26.14 ± 3.37 kg/m² versus 24.06 ± 2.70 kg/m²), EFV (144.38 ± 52.66 cm³ versus 119.50 ± 42.82 cm³), FBG (6.13 mmol/L versus 5.30 mmol/L), TC (4.13 mmol/L versus 3.66 mmol/L), TG (1.77 mmol/L versus 1.31 mmol/L), LDL-C (2.37 ± 0.77 mmol/L versus 2.21 ± 0.92 mmol/L), Apo-B (0.86 ± 0.28 g/L versus 0.78 ± 0.30 g/L), and UA (356.16 ± 97.20 µmol/L versus 323.02 ± 78.45 µmol/L) levels; the DM [44 (41.1%) versus 29 (16.7%)], hypertension [84 (78.5%) versus 109 (62.6%)], and myocardial ischemia [72 (67.3%) versus 68 (39.1%)] were also higher (all P < 0.05) (Table 2). Table 2Comparison of clinical data between the MASLD group and the no MASLD groupMASLD (n = 107)NO MASLD (n = 174)P ValueAge, years60.37 ± 10.1062.68 ± 9.970.062Male, n (%)55 (51.4)97 (55.8)0.478BMI, kg/m²26.14 ± 3.3724.06 ± 2.70< 0.001*Abdominal obesity, n (%)85 (79.4)102 (58.6)< 0.001*Current smoking, n (%)42 (39.3)50 (28.7)0.015*Hypertension, n (%)84 (78.5)109 (62.6)0.005*Hyperlipidemias, n (%)58 (54.2)64 (36.8)0.004*DM, n (%)44 (41.1)29 (16.7)< 0.001*MPI, n (%)72 (67.3)68 (39.1)< 0.001*EFV, cm3144.38 ± 52.66119.50 ± 42.82< 0.001*FBG, mmol/L6.13 (5.36, 7.24)5.30 (4.89, 6.28)< 0.001*TC, mmol/L4.13 (3.32, 4.97)3.66 (3.08, 4.49)0.010*TG, mmol/L1.77 (1.30, 2.63)1.31 (0.98, 1.77)< 0.001*HDL-C, mmol/L1.06 ± 0.321.21 ± 0.26< 0.001*LDL-C, mmol/L2.37 ± 0.772.21 ± 0.920.032*Apo-A1, g/L1.17 ± 0.251.23 ± 0.240.038*Apo-B, g/L0.86 ± 0.280.78 ± 0.300.010*Creatinine, µmol/L67.02 ± 22.6869.82 ± 15.440.050UA, µmol/L356.16 ± 97.20323.02 ± 78.450.003*BMI, body mass, index; DM, diabetes mellitus; CACS, coronary artery calcification score; MASLD, Metabolic dysfunction–associated steatotic liver disease; MPI, myocardial perfusion ischemia; EFV, epicardial fat volume; FBG, fasting blood glucose; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high‐density lipoprotein cholesterol; UA, uric acid. *P<0.05 Table 2Comparison of clinical data between the MASLD group and the no MASLD groupMASLD (n = 107)NO MASLD (n = 174)P ValueAge, years60.37 ± 10.1062.68 ± 9.970.062Male, n (%)55 (51.4)97 (55.8)0.478BMI, kg/m²26.14 ± 3.3724.06 ± 2.70< 0.001*Abdominal obesity, n (%)85 (79.4)102 (58.6)< 0.001*Current smoking, n (%)42 (39.3)50 (28.7)0.015*Hypertension, n (%)84 (78.5)109 (62.6)0.005*Hyperlipidemias, n (%)58 (54.2)64 (36.8)0.004*DM, n (%)44 (41.1)29 (16.7)< 0.001*MPI, n (%)72 (67.3)68 (39.1)< 0.001*EFV, cm3144.38 ± 52.66119.50 ± 42.82< 0.001*FBG, mmol/L6.13 (5.36, 7.24)5.30 (4.89, 6.28)< 0.001*TC, mmol/L4.13 (3.32, 4.97)3.66 (3.08, 4.49)0.010*TG, mmol/L1.77 (1.30, 2.63)1.31 (0.98, 1.77)< 0.001*HDL-C, mmol/L1.06 ± 0.321.21 ± 0.26< 0.001*LDL-C, mmol/L2.37 ± 0.772.21 ± 0.920.032*Apo-A1, g/L1.17 ± 0.251.23 ± 0.240.038*Apo-B, g/L0.86 ± 0.280.78 ± 0.300.010*Creatinine, µmol/L67.02 ± 22.6869.82 ± 15.440.050UA, µmol/L356.16 ± 97.20323.02 ± 78.450.003*BMI, body mass, index; DM, diabetes mellitus; CACS, coronary artery calcification score; MASLD, Metabolic dysfunction–associated steatotic liver disease; MPI, myocardial perfusion ischemia; EFV, epicardial fat volume; FBG, fasting blood glucose; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high‐density lipoprotein cholesterol; UA, uric acid. *P<0.05 Comparison of clinical data between the MASLD group and the no MASLD group BMI, body mass, index; DM, diabetes mellitus; CACS, coronary artery calcification score; MASLD, Metabolic dysfunction–associated steatotic liver disease; MPI, myocardial perfusion ischemia; EFV, epicardial fat volume; FBG, fasting blood glucose; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high‐density lipoprotein cholesterol; UA, uric acid. *P<0.05 The influencing factors of myocardial ischemia As shown in Table 3, univariate logistic regression analysis indicated that MASLD (OR = 5.39, 95% CI: 3.15 ~ 9.25, P < 0.01), current smoking (OR = 1.97, 95% CI: 1.17 ~ 3.30, P = 0.011), DM (OR = 2.07, 95% CI: 1.19 ~ 3.57, P = 0.009), and EFV (OR = 1.01, 95% CI: 1.00 ~ 1.01, P = 0.019) were significant risk factors for myocardial ischemia. In the multivariate logistic regression analysis adjusting traditional risk factors for myocardial ischemia (such as smoking, obesity, hypertension, hyperlipidemia, and DM), CACS, EFV, and the degree of coronary artery stenosis. MASLD is an independent risk factor for myocardial ischemia (OR = 4.97, 95% CI: 2.68 ~ 9.24, P < 0.001). Additionally, current smoking was also identified as a risk factor for myocardial ischemia (OR = 1.84, 95% CI: 1.04 ~ 3.25, P = 0.035). Table 3Univariate and multivariate logistic regression analysis for myocardial ischemiaVariableUnivariate analysisMultivariate analysisOR (95% CI)P ValueOR (95% CI)P ValueGenders (male)1.35 (0.85 ~ 2.17)0.207Age (≥ 60)0.80 (0.50 ~ 1.30)0.367Current smoking1.97 (1.17 ~ 3.30)0.011*1.84 (1.04 ~ 3.25)0.035*BMI ≥ 241.67 (1.04 ~ 2.71)0.035*1.30 (0.72 ~ 2.34)0.379Hypertension1.38 (0.83 ~ 2.29)0.213Hyperlipidemias0.90 (0.56 ~ 1.45)0.668DM2.07 (1.19 ~ 3.57)0.009*1.70 (0.91 ~ 3.20)0.098MASLD5.39 (3.15 ~ 9.25)< 0.001*4.97 (2.68 ~ 9.24)< 0.001*CACS>01.39 (0.87 ~ 2.23)0.168EFV1.01 (1.00 ~ 1.01)0.019*1.00 (1.00 ~ 1.01)0.667Obstructive CAD1.57 (0.98 ~ 2.52)0.063BMI, body mass, index; DM, diabetes mellitus; CACS, coronary artery calcification score; MASLD, Metabolic dysfunction–associated steatotic liver disease; EFV, epicardial fat volume; OR, odd ratio; *P<0.05 Table 3Univariate and multivariate logistic regression analysis for myocardial ischemiaVariableUnivariate analysisMultivariate analysisOR (95% CI)P ValueOR (95% CI)P ValueGenders (male)1.35 (0.85 ~ 2.17)0.207Age (≥ 60)0.80 (0.50 ~ 1.30)0.367Current smoking1.97 (1.17 ~ 3.30)0.011*1.84 (1.04 ~ 3.25)0.035*BMI ≥ 241.67 (1.04 ~ 2.71)0.035*1.30 (0.72 ~ 2.34)0.379Hypertension1.38 (0.83 ~ 2.29)0.213Hyperlipidemias0.90 (0.56 ~ 1.45)0.668DM2.07 (1.19 ~ 3.57)0.009*1.70 (0.91 ~ 3.20)0.098MASLD5.39 (3.15 ~ 9.25)< 0.001*4.97 (2.68 ~ 9.24)< 0.001*CACS>01.39 (0.87 ~ 2.23)0.168EFV1.01 (1.00 ~ 1.01)0.019*1.00 (1.00 ~ 1.01)0.667Obstructive CAD1.57 (0.98 ~ 2.52)0.063BMI, body mass, index; DM, diabetes mellitus; CACS, coronary artery calcification score; MASLD, Metabolic dysfunction–associated steatotic liver disease; EFV, epicardial fat volume; OR, odd ratio; *P<0.05 Univariate and multivariate logistic regression analysis for myocardial ischemia BMI, body mass, index; DM, diabetes mellitus; CACS, coronary artery calcification score; MASLD, Metabolic dysfunction–associated steatotic liver disease; EFV, epicardial fat volume; OR, odd ratio; *P<0.05 The relationship between MASLD and myocardial ischemia A generalized additive model was employed to verify the linear relationship between the severity of MASLD fat infiltration and myocardial ischemia. After adjusting for age, gender, BMI, hypertension, hyperlipidemia, DM, CACS, EFV, and the degree of coronary stenosis, there is a linear relationship between the CT density ratio of liver and spleen and the risk of myocardial ischemia, as shown in Fig. 2. Fig. 2Validation of the relationship between MASLD and myocardial ischemia using a generalized additive model. The Y-axis represents the relative risk of myocardial ischemia occurrence, while the X-axis represents the liver-to-spleen CT density ratio, with smaller ratios indicating greater severity of MASLD. The results show that after adjusting for age, gender, smoking history, hypertension, hyperlipidemia, DM, BMI, CACS, and EFV, the relative risk of myocardial ischemia gradually increases as the liver/spleen CT density ratio decreases Validation of the relationship between MASLD and myocardial ischemia using a generalized additive model. The Y-axis represents the relative risk of myocardial ischemia occurrence, while the X-axis represents the liver-to-spleen CT density ratio, with smaller ratios indicating greater severity of MASLD. The results show that after adjusting for age, gender, smoking history, hypertension, hyperlipidemia, DM, BMI, CACS, and EFV, the relative risk of myocardial ischemia gradually increases as the liver/spleen CT density ratio decreases Subgroup population The total population was divided into an obstructive-CAD group (155 cases) and without obstructive CAD group (126 cases). The numbers of myocardial ischemia patients with obstructive CAD and without obstructive CAD are shown in Fig. 3. Univariate logistic regression analysis revealed that smoking, DM, MASLD, and the degree of coronary stenosis are risk factors for myocardial ischemia in the obstructive CAD group (Table 4), while overweight (BMI ≥ 24), MASLD, and EFV are risk factors for myocardial ischemia in the people without obstructive CAD (both P < 0.05). The results of multivariate logistic regression analysis indicated that smoking and MASLD are independent risk factors for myocardial ischemia in the obstructive CAD group (OR = 2.50, 95% CI:1.09 ~ 5.71, P = 0.030, OR = 5.04, 95% CI: 1.81 ~ 14.00, P = 0.002), and MASLD is an independent risk factor for myocardial ischemia in patients without obstructive CAD (OR = 7.43, 95% CI: 2.69 ~ 20.52, P < 0.001). Typical case is depicted in Figs. 4. Fig. 3Subgroup analysis of the MASLD and myocardial ischemia. OR, odds ratio; CI, confidence interval; CAD, coronary artery disease. The results show that after adjusting for age, gender, smoking, hypertension, hyperlipidemia, DM, BMI, CACS, EFV and degree of coronary artery stenosis (including stenosis = 0%) Subgroup analysis of the MASLD and myocardial ischemia. OR, odds ratio; CI, confidence interval; CAD, coronary artery disease. The results show that after adjusting for age, gender, smoking, hypertension, hyperlipidemia, DM, BMI, CACS, EFV and degree of coronary artery stenosis (including stenosis = 0%) Table 4Univariate and multivariate logistic regression analysis for myocardial ischemia in obstructive and without obstructive CADVariableObstructive CADWithout obstructive CADUnivariate analysisMultivariate analysisUnivariate analysisMultivariate analysisOR (95% CI)P ValueOR (95% CI)P ValueOR (95% CI)P ValueOR (95% CI)P ValueGender (male)1.71 (0.89 ~ 3.29)0.1100.88 (0.43 ~ 1.78)0.715Age (≥ 60)0.68 (0.34 ~ 1.32)0.2520.86 (0.43 ~ 1.75)0.686Current smoking2.36 (1.18 ~ 4.72)0.015*2.50 (1.09 ~ 5.71)0.030*1.67 (0.76 ~ 3.69)0.203BMI ≥ 241.47 (0.78 ~ 2.79)0.2372.25 (1.05 ~ 4.79)0.036*2.05 (0.74 ~ 5.65)0.165Hypertension1.69 (0.85 ~ 3.36)0.1331.07 (0.50 ~ 2.28)0.859Hyperlipidemias1.01 (0.53 ~ 1.94)0.9740.87 (0.43 ~ 1.76)0.702DM4.52 (1.98 ~ 10.30)< 0.001*2.29 (0.86 ~ 6.10)0.0600.82 (0.36 ~ 1.89)0.644MASLD5.70 (2.68 ~ 12.12)< 0.001*5.04 (1.81 ~ 14.00)0.002*5.16 (2.37 ~ 11.19)< 0.001*7.43 (2.69 ~ 20.52)< 0.001*CACS>01.40 (0.69 ~ 2.83)0.3531.00 (0.47 ~ 2.13)0.993EFV1.00 (1.00 ~ 1.01)0.3831.01 (1.00 ~ 1.02)0.023*1.00 (0.99 ~ 1.01)0.953Degree of stenosis1.03 (1.00 ~ 1.05)0.021*1.07 (0.39 ~ 2.93)0.9021.37 (0.65 ~ 2.89)0.406BMI, body mass, index; DM, diabetes mellitus; CACS, coronary artery calcification score; MASLD, metabolic dysfunction–associated steatotic liver disease; EFV, epicardial fat volume; OR, odd ratio; *P<0.05 Table 4Univariate and multivariate logistic regression analysis for myocardial ischemia in obstructive and without obstructive CADVariableObstructive CADWithout obstructive CADUnivariate analysisMultivariate analysisUnivariate analysisMultivariate analysisOR (95% CI)P ValueOR (95% CI)P ValueOR (95% CI)P ValueOR (95% CI)P ValueGender (male)1.71 (0.89 ~ 3.29)0.1100.88 (0.43 ~ 1.78)0.715Age (≥ 60)0.68 (0.34 ~ 1.32)0.2520.86 (0.43 ~ 1.75)0.686Current smoking2.36 (1.18 ~ 4.72)0.015*2.50 (1.09 ~ 5.71)0.030*1.67 (0.76 ~ 3.69)0.203BMI ≥ 241.47 (0.78 ~ 2.79)0.2372.25 (1.05 ~ 4.79)0.036*2.05 (0.74 ~ 5.65)0.165Hypertension1.69 (0.85 ~ 3.36)0.1331.07 (0.50 ~ 2.28)0.859Hyperlipidemias1.01 (0.53 ~ 1.94)0.9740.87 (0.43 ~ 1.76)0.702DM4.52 (1.98 ~ 10.30)< 0.001*2.29 (0.86 ~ 6.10)0.0600.82 (0.36 ~ 1.89)0.644MASLD5.70 (2.68 ~ 12.12)< 0.001*5.04 (1.81 ~ 14.00)0.002*5.16 (2.37 ~ 11.19)< 0.001*7.43 (2.69 ~ 20.52)< 0.001*CACS>01.40 (0.69 ~ 2.83)0.3531.00 (0.47 ~ 2.13)0.993EFV1.00 (1.00 ~ 1.01)0.3831.01 (1.00 ~ 1.02)0.023*1.00 (0.99 ~ 1.01)0.953Degree of stenosis1.03 (1.00 ~ 1.05)0.021*1.07 (0.39 ~ 2.93)0.9021.37 (0.65 ~ 2.89)0.406BMI, body mass, index; DM, diabetes mellitus; CACS, coronary artery calcification score; MASLD, metabolic dysfunction–associated steatotic liver disease; EFV, epicardial fat volume; OR, odd ratio; *P<0.05 Univariate and multivariate logistic regression analysis for myocardial ischemia in obstructive and without obstructive CAD BMI, body mass, index; DM, diabetes mellitus; CACS, coronary artery calcification score; MASLD, metabolic dysfunction–associated steatotic liver disease; EFV, epicardial fat volume; OR, odd ratio; *P<0.05 Fig. 4Typical case of non-obstructive coronary artery disease: The patient is a 66-year-old female admitted for “recurrent chest pain for over 10 days.” 4a: Coronary angiography (CAG) results show 30% stenosis in the mid-segment of the LAD, no significant stenosis in the LCX or RCA. 4b: The stress-rest myocardial perfusion images (with images 1, 3 as stress images and 2, 4 as rest images) display reversible myocardial ischemia in the mid-segment of the left ventricular anterior wall, near the apex and apex(indicated by white arrows). 4c: CT results show an average liver CT density of 22 HU and an average spleen CT density of 54 HU, with a liver/spleen ratio < 1 Typical case of non-obstructive coronary artery disease: The patient is a 66-year-old female admitted for “recurrent chest pain for over 10 days.” 4a: Coronary angiography (CAG) results show 30% stenosis in the mid-segment of the LAD, no significant stenosis in the LCX or RCA. 4b: The stress-rest myocardial perfusion images (with images 1, 3 as stress images and 2, 4 as rest images) display reversible myocardial ischemia in the mid-segment of the left ventricular anterior wall, near the apex and apex(indicated by white arrows). 4c: CT results show an average liver CT density of 22 HU and an average spleen CT density of 54 HU, with a liver/spleen ratio < 1 Discussion This study investigated the relationship between MASLD and myocardial ischemia in patients suspected or known of CAD. The results showed that (1) the incidence of myocardial ischemia in MASLD patients was significantly higher than in non-MASLD, and the probability of developing myocardial ischemia in MASLD patients is 4.39 times higher than that in non-MASLD patients; (2) MASLD is an independent risk factor for myocardial ischemia, independent of traditional risk factors, EFV, CACS, and obstructive CAD; (3) subgroup analyses revealed that regardless of whether patients have obstructive CAD, MASLD and myocardial ischemia are significantly associated, especially in patients without obstructive CAD, where the risk of myocardial ischemia is increased by 6.43 times. MASLD is the globally most common chronic liver disease [10], and approximately 38% of participants in this study had MASLD, consistent with previous findings. MASLD is not only a liver disease but also a marker of systemic metabolic dysregulation, often coexisting with metabolic syndrome factors such as obesity, hypertension, DM, and hyperlipidemia [30]. The results showed patients with MASLD had a higher BMI, EFV, FBG, TC, TG, LDL-C, creatinine, UA, constituent ratio of DM, abdominal obesity, hyperglycemia and hyperlipidemia, and compared to patients without MASLD, and their HDL-C levels were lower than those of patients without MASLD, which is consistent with the results of previous studies. Furthermore, the study results showed that the proportion of MASLD patients with a smoking history was significantly higher than that of non-MASLD patients. This may be because nicotine and carbon monoxide in cigarettes stimulate the release of catecholamines, elevating free fatty acid levels. These acids are converted into triglycerides by the liver and fat tissue. Catecholamines also promote fat breakdown, increasing blood triglyceride levels. Smoking thus raises blood triglycerides and may lead to fatty liver disease [31]. This study found that the prevalence of MASLD in the myocardial ischemia group was significantly higher, indicating a close association between MASLD and myocardial ischemia, and confirming that MASLD is an independent risk factor for myocardial ischemia. Similar to our results, Ren et al. [15] indicated that MASLD was associated with myocardial ischemia, independent of traditional cardiovascular risk factors and CCTA characteristics. Interestingly, in our multivariate analysis, diabetes did not emerge as an independent predictor of myocardial ischemia. Additionally, the study results also indicated that there was no collinearity relationship between diabetes and MASLD. This might be attributed to the relatively low proportion of diabetic patients in our study cohort. Meanwhile, MASLD might mediate to some extent the cardiovascular risks that were originally attributed to diabetes. We used a SDS ≥ 2 to define myocardial ischemia. This threshold is widely accepted for detecting reversible perfusion abnormalities due to its high specificity. Although patients with known myocardial infarction were excluded, asymptomatic or undiagnosed infarctions may still be present. However, as SDS primarily captures inducible ischemia and is unlikely to misclassify fixed defects as reversible, it enhances the reliability of our findings. The study shows that as the liver/spleen CT density ratio decreases, the risk of myocardial ischemia increases. This indicates that greater liver fat infiltration in MASLD is linked to a higher likelihood of myocardial ischemia, confirming a correlation between MASLD severity and ischemic risk [32]. The severity of MASLD is closely related to the degree of fat accumulation in the liver and the extent of liver fibrosis, which may further exacerbate systemic metabolic dysregulation and inflammatory responses, thereby increasing the risk of myocardial ischemia [33]. Furthermore, evidence from Vita et al. [34] supports the link between NAFLD and coronary microvascular dysfunction (CMD), reinforcing the hypothesis that hepatic steatosis may be a systemic indicator of coronary microvascular dysfunction. Notably, although most patients in our study had only mild hepatic steatosis, MASLD still emerged as a strong predictor of myocardial ischemia. This observation is both novel and clinically significant. One possible explanation is that even mild hepatic steatosis reflects underlying metabolic dysregulation, systemic inflammation, endothelial dysfunction, and coronary microvascular impairment—factors [32] that may not be adequately captured by anatomical imaging such as CACS. Therefore, MASLD may act as a sensitive indicator of early functional abnormalities in coronary circulation, consistent with emerging data linking MASLD to CMD and impaired coronary flow reserve. The association between MASLD and atherosclerosis has been extensively demonstrated in various populations [12], and our findings further extend this connection to myocardial ischemia independent of epicardial obstruction. Subgroup analysis shows that, regardless of the presence or absence of epicardial vascular obstruction and the degree of coronary stenosis, MASLD is an independent risk factor for the occurrence of myocardial ischemia, especially in the without obstructive CAD population, the risk of myocardial ischemia increased by 6,34 times. Studies have shown that more than half of patients with myocardial ischemia have without obstructive CAD based on their CAG results [7]. The pathogenesis of myocardial ischemia encompasses not only structural alterations in the coronary arteries, such as occlusion, but also functional abnormalities, including vasoconstriction and coronary microvascular dysfunction [6]. Patients with MASLD often have elevated LDL and triglyceride levels, which can deposit on arterial walls and form plaques, promoting atherosclerosis. This may cause coronary artery narrowing or blockage, leading to myocardial ischemia [35]. In patients without obstructive CAD, MASLD may directly or indirectly contribute to myocardial ischemia through mechanisms such as insulin resistance, activation of the renin-angiotensin and sympathetic nervous systems, systemic inflammation, oxidative stress, and gut microbiota changes [35, 36]. MASLD-related liver fat accumulation leads to insulin resistance, increasing plasma free fatty acids. This worsens hepatic fat buildup and causes myocardial insulin resistance, reducing cardiac glucose uptake and increasing fatty acid oxidation. As a result, the heart receives insufficient energy, contributing to myocardial ischemia [32]. As MASLD progresses, liver fat triggers hepatocyte injury, activating inflammatory responses and releasing cytokines such as TNF-α and IL-6. These molecules impair vascular function and worsen myocardial ischemia [14, 37]. Furthermore, systemic oxidative stress caused by MASLD increases the risk of myocardial ischemia. Liver fat overload leads to mitochondrial dysfunction and oxidative stress, which is intensified during myocardial ischemia due to hypoxia. This accelerates myocardial damage and promotes the progression of ischemic heart disease [38]. These mechanisms may also affect coronary microvascular function, further contributing to myocardial ischemia. This study confirms that MASLD is an independent risk factor for myocardial ischemia, providing a potential target and theoretical basis for precise prevention and treatment of myocardial ischemia, especially for patients without obstructive CAD. The research by Lin et al. [39] indicates that NAFLD predicts long-term risk of MACE in asymptomatic individuals. Comprehensive management of MASLD patients, including lifestyle adjustments (such as diet control, weight management, and increased physical exercise) and pharmacological interventions (such as insulin sensitizers, antioxidants, and statins), can help reduce the risk of myocardial ischemia and MACE [40]. The modern definition emphasizes that precise prevention and treatment of myocardial ischemia plays a crucial role in the management of chronic CAD [1]. By providing health education, screening, early prevention, and comprehensive management (including controlling hypertension, hyperlipidemia, DM, obesity, and smoking cessation), the incidence of myocardial ischemia can be significantly reduced. Therefore, screening and assessment for MASLD should be considered in patients with suspected or known CAD, especially in the without obstructive CAD population. Limitation This study has certain limitations. Firstly, it utilized a retrospective study design, which carries a risk of information bias. Its retrospective nature limits the ability to infer causality. While we found a strong and independent association between MASLD and myocardial ischemia, we cannot establish a causal relationship. Prospective longitudinal studies are needed to determine whether treatment of MASLD can reduce ischemic burden or cardiovascular events. Secondly, as a single-center study with a small sample size, the stability and reliability of the results may be affected. Most patients in this study had mild MASLD fat infiltration, and MASLD patients were not classified into mild, moderate, and severe categories according to standard criteria. Additionally, this study did not use the fractional flow reserve (FFR), so it could only assess whether the patient had ischemia, but not quantitatively analyze the severity of the ischemia. This study only conducted a correlation analysis and did not involve research on patient outcomes or intervention for MASLD, so it was unable to evaluate the improvement in myocardial ischemia after fatty liver treatment. Conclusions In conclusion, our study validates that MASLD is an independent risk factor for myocardial ischemia, after adjusting for traditional risk factors, CACS, EFV and degree of coronary stenosis. The incidence of myocardial ischemia increases with the occurrence and severity of MASLD. Especially in patients without obstructive CAD the impact of MASLD on myocardial ischemia risk is more significant. It provides an important theoretical basis for the early precise prevention and treatment of myocardial ischemia.